Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 2, 2002, Pages 149-160

  Turecek, Peter L ^a   Siekmann, Jürgen ^a   Schwarz, Hans Peter ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Collagen binding activity; FVIII vWF concentrates; Heparin affinity chromatography; Ristocetin cofactor activity; von Willebrand disease; von Willebrand factor; vWF

Indexed keywords

COLLAGEN; HEPARIN; RISTOCETIN A; VON WILLEBRAND FACTOR;

AFFINITY CHROMATOGRAPHY; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; PRIORITY JOURNAL; RECEPTOR BINDING; REPRODUCIBILITY; STANDARD; STRUCTURE ACTIVITY RELATION; VON WILLEBRAND DISEASE;

AGGLUTINATION TESTS; CHROMATOGRAPHY, AFFINITY; COLLAGEN; DIMERIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HUMANS; MOLECULAR PROBE TECHNIQUES; PROTEIN BINDING; RISTOCETIN; STRUCTURE-ACTIVITY RELATIONSHIP; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0036232506     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-27817     Document Type: Article

References (69)

1. Structure and function of von Willebrand factor
2. Biochemistry and genetics of von Willebrand factor
3. Structure-function relationship of the A1 domain of von Willebrand factor
4. Substructure of human von Willebrand factor
5. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers
6. Triplet structure of human von Willebrand factor
7. Localization of a heparin binding domain peptide of human von Willebrand factor
8. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine scanning mutagenesis
9. Structure and function of the von Willebrand factor A1 domain: Analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation
10. Molecular mechanism and classification of von Willebrand disease
11. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation
12. A method for assaying von Willebrand factor (ristocetin cofactor)
13. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor
14. An ELISA test for the binding of von Willebrand factor antigen to collagen
15. Development of a single collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease
16. The determination of von Willebrand factor activity by collagen binding assay
17. Structure of ristocetin A
18. On the structure and mode of action of the antibiotic ristocetin A
19. Aspects of molecular recognition: Solvent exclusion and dimerization of the antibiotic ristocetin when bound to a model bacterial cell-wall precursor
20. Cleavage of rhamnose from ristocetin A removes its ability to induce platelet aggregation
21. The chemical basis for the action of the vancomycin group of antibiotics
22. Ristocetin-induced thrombocytopenia; site and mechanism of action
23. Ristocetin-a new tool in the investigation of platelet aggregation
24. Ristocetin: A means of differentiating von Willebrand's disease into two groups
25. Fixation platelets and platelet agglutination aggregation tests
26. A simple quantitative assay for ristocetin cofactor activity using microtiter plate and ELISA plate reader
27. von Willebrand ristocetin cofactor: Fast and precise determination on coagulation analyzers
28. Willebrand and ristocetin. I. Mechanism of ristocetin-induced platelet aggregation
29. Studies on the mechanism of ristocetin-induced platelet agglutination
30. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets
31. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib
32. von Willebrand disease
33. A role for von Willebrand factor proline residues 702-704 in ristocetin mediated binding to platelet glycoprotein Ib
34. Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin
35. von Willebrand's disease
36. Laboratory testing for von Willebrand's disease: An assessment of current diagnostic practice and efficiency by means of a multi-laboratory survey
37. Factor VIII-related activities in therapeutic concentrates
38. Plasma derived von Willebrand factor preparations: Collagen binding and ristocetin cofactor activities
39. Rapid diagnosis of von Willebrand's disease using ELISA technology
40. A simple test for the determination of the von Willebrand factor function: The collagen binding activity
41. Collagen binding assay for von Willebrand factor (VWF:CBA): Detection of von Willebrand's disease (vWD), and discrimination of vWD subtypes, depends on collagen source
42. The interaction of von Willebrand factor (vWF) with collagen: Investigation of vWF-binding sites in the collagen molecule
43. Isolation and characterization of a collagen binding domain in human von Willebrand factor
44. Localization of binding sites within human von Willebrand factor for monomeric type III collagen
45. Collagen: An overview and update
46. Isolation and characterization of collagens and procollagens
47. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects
48. Type 2M von Willebrand disease: F6606I and I662F mutations in the glycoprotein binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets
49. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay
50. Human coagulation factor VIII, freeze-dried
51. A sensitive ELISA for von Willebrand factor (vWF:Ag)
52. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use
53. A two-site, monoclonal antibody-based immunoassay for von Willebrand factor - Demonstration that vWF function resides in a conformational epitope
54. Assays for von Willebrand factor functional activity: A UK NEQAS survey
55. A method for measuring activated factor VIII in plasma
56. Assay of ristocetin cofactor using fixed platelets and a platelet counting technique
57. The complex multimeric composition of factor VIII/von Willebrand factor
58. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease
59. Visualization of von Willebrand factor multimers by immunoenzymatic stain using avidin-biotin peroxidase complex
60. The hemostatic potency of von Willebrand factor in FVIII/vWF concentrates is reflected by affinity to immobilized heparin
61. A comparison of two macroscopic platelet agglutination assays for von Willebrand factor
62. Laboratory assays for von Willebrand factor: Relative contribution to the diagnosis of von Willebrand's disease
63. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu - Evidence of the importance of the multimerization degree of vWF
64. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII
65. Laboratory assessment as a critical component of the appropriate diagnosis and subclassification of von Willebrand's disease
66. von Willebrand disease in a pediatric-based population: Comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay
67. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease
68. New treatments of von Willebrand disease: Plasma-derived von Willebrand factor concentrates
69. Successful treatment of patients with von Willebrand disease using a high purity double virus inactivated FVIII/vWF concentrate (IMMUNATE)